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and DCT were similar (50%) with no signiﬁcant differences in
frequency of viral, fungal or bacterial infections (P  0.74). Most
importantly, infection was the primary cause of death at 100 days
for SCT (9/20) whereas for DCT, there were no infection-related
deaths! TNC and CD34 cell dose did not differ between engraft-
ing and non-engrafting units; however, we found that the engraft-
ing units had a lower absolute lymphocyte count (ALC) in 8/10
evaluable cases.
Conclusion: DCT is an effective approach to overcome the
TNC dose-limiting therapeutic beneﬁt of CB transplantation.
Although 100-day post-transplant infection frequency remains
high, deaths from infection are markedly reduced and OS is
signiﬁcantly improved in DCT recipients; however, additional
studies are needed to deﬁne the mechanism. For DCT, the
engrafting unit does not have a higher TNC or CD34 cell dose
but, paradoxically, a lower ALC dose may be predictive.
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HLA MATCHING FOR TRANSPLANTATION: LESSONS FROM BONE
MARROW
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HLA matching strongly affects the outcome of unrelated donor
bone marrow transplantation. How these effects translate to other
hematopoietic cell sources, such as cord blood and peripheral
blood stem cells, is only partially clariﬁed. Much of the available
data concerning bone marrow transplantation comes from studies
published by the Japan Marrow Donor Program, the Fred
Hutchinson Cancer Research Center, and the National Marrow
Donor Program (NMDP). In general, the studies show that match-
ing for HLA A, B, C and DRB1 inﬂuences important endpoints
such as survival, engraftment and graft versus host disease. Al-
though antigen level matching is important, allele level mismatches
are also detrimental. Matching for HLA DQ is important in some
studies, but not in others. A clear role for HLA DP matching has
not been identiﬁed.
For bone marrow transplantation, the NMDP recommends 8
of 8 allele matching at HLA A, B, C and DRB1. If this level of
matching cannot be achieved, a single allele mismatch is pref-
erable over an antigen mismatch. At the present time, each locus
should be considered of equal weight, that is, no locus is clearly
more important than the others. When multiple mismatches are
unavoidable, it is unclear how to compare alleles and antigens,
e.g., are two mismatched alleles preferable to a single antigen?
More data are needed to answer this question [1-5].
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ANALYSIS OF 608 UMBILICAL CORD BLOOD (UCB) TRANSPLANTS:
HLA-MATCH IS A CRITICAL DETERMINANT OF TRANSPLANT-RELATED
MORTALITY (TRM) IN THE POST-ENGRAFTMENT PERIOD EVEN IN THE
ABSENCE OF ACUTE GRAFT-VS-HOST DISEASE (AGVHD)
Barker, J., Scaradavou, A., Stevens, C., Rubinstein, P. New York Blood
Center (NYBC) National Cord Program and Memorial Sloan-Kettering
Cancer Center, New York, NY.
With the recognition of the critical importance of UCB cell
dose upon hematopoietic recovery, neutrophil recovery after
UCB transplantation (UCBT) has improved. However, TRM in
the early post-engraftment period (days 30-180) remains a bar-
rier to transplant success. How graft characteristics impact upon
the risk for TRM during this period is important but has not
been well characterized. Therefore, we analyzed the impact of
cell dose and HLA-match upon TRM between days 30-180 in
recipients of single unit 3-6/6 HLA-A,B antigen and DRB1
allele matched UCBT who were transplanted for leukemia or
myelodysplasia with units from the National Cord Blood Pro-
gram and achieved sustained donor engraftment. Patients dying
from days 0 to 29 or those with primary or secondary graft
failure were excluded, and patients were censored at the time of
relapse.
Six hundred eight patients fulﬁlled study criteria and had a
median age of 9.0 years (range 0.4-58 years). The cumulative
incidence of TRM was 36% (95% CI: 32-39). Using 2.5-4.9  107
TNC/kg as the reference (n  229), the impact of cell dose was
analyzed. While patients (n  141) receiving a lower dose of
0.7-2.4 had a relative risk (RR) of TRM of 1.5 (P  0.009) during
this period, TRM in patients receiving higher doses were similar to
the reference [5.0-9.9 (n  160) RR 0.9, P  0.4; 10.0 (n  78)
RR 0.8, P  0.4)]. However, HLA-match had an impact upon
TRM at all levels of match [reference: 5/6 recipients (n 194); 6/6
(n  32) RR 0.3, P  0.063; 4/6 (n  342) RR 1.7, P  0.001; 3/6
(n 40) RR 2.2, P 0.003]. To exclude the possibility that disease
stage contributed to this ﬁnding, a multivariate Cox regression
analysis was performed that included TNC dose, HLA-match and
disease stage, and showed that low cell dose and HLA-mismatch
were the signiﬁcant predictors of TRM. Further, when patients
were divided into those without signiﬁcant aGVHD (only grade 0
or 1) (n  292) vs patients with grade 2-4 aGVHD (n  301), the
effect of HLA-match on TRM was most pronounced in those
without signiﬁcant aGVHD [reference: 5/6 recipients (n  102);
6/6 (n  25) RR 0.0, P  NS; 4/6 (n  151) RR 2.4, P  0.004;
3/6 (n  14) RR 2.8, P  0.050]. Of the transplant-related deaths
(n  60) from days 30-180 in this “without signiﬁcant aGVHD”
group, infection was reported to be a major cause of death in 36
(60%).
In summary, above the threshold of 2.5 107 TNC/kg, cell dose
has no demonstrable effect on the risk for day 180 TRM in the
post-engraftment period, whereas the adverse impact of HLA-
mismatch is both striking and retained even in the absence of
aGVHD. We postulate that the adverse effect of HLA-mismatch is
mediated not only by induction of aGVHD, but also by an effect
on immune reconstitution as manifested by death from infection.
These data have signiﬁcant implications for graft selection imply-
ing that both dose and HLA-match should be considered, and
investigation of how to “trade-off” each of these factors should be
a priority. Further, it argues that recipients of HLA-mismatched
grafts will require aggressive supportive care and strategies to
augment immune reconstitution. Finally, improved outcome in
UCBT may be dependent upon the ability to obtain units that are
both of sufﬁcient size and match which will require an increase in
the global UCB inventory.
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